The Bone Tumor drugs in development market research report provides comprehensive information on the therapeutics under development for Bone Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Bone Tumor. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Bone Tumor and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Bone Tumor by 11 companies/universities/institutes. The top development phase for Bone Tumor is preclinical with three drugs in that stage. The Bone Tumor pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Bone Tumor pipeline products market are: Jiangsu Hansoh Pharmaceutical Group, Genor BioPharma and Eden Biologics.
The key targets in the Bone Tumor pipeline products market include Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or RANKL or CD254 or TNFSF11), and Tumor Necrosis Factor Receptor Superfamily Member 11A (Osteoclast Differentiation Factor Receptor or Receptor Activator Of NF-KB or RANK or CD265 or TNFRSF11A).
The key mechanisms of action in the Bone Tumor pipeline product include Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or RANKL or CD254 or TNFSF11) Inhibitor with eight drugs in Pre-Registration. The Bone Tumor pipeline products include three routes of administration with the top ROA being Subcutaneous and three key molecule types in the Bone Tumor pipeline products market including Monoclonal Antibody, and Oncolytic Virus.
Bone Tumor overview
Bone Tumor or bone cancer affecting any bone in the body. Most of the bone cancers are benign while some are malignant or cancerous. This occurs when bone cells divide uncontrollably. Osteosarcoma, Ewing sarcoma, chondrosarcoma are the types of sarcomas. Most commonly occurs in children than in adults. Etiology is idiopathic. Pain in bones, swelling, fatigue, fever, weight loss are some common symptoms. Radiographic findings with X-ray, MRI, CT-scan, biopsy and other required tests are performed to diagnose the condition. Benign tumors can be managed with symptomatic medications, while for malignant chemotherapy, radiation therapy and eventually in severe cases surgery is chosen. Bone cancer can be metastatic and spreads to breast, lungs, thyroid, renal, pancreas.
For a complete picture of Bone Tumor’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
